WHITEPAPER |
THE NUTS & BOLTS OF DUE DILIGENCE IN BIOPHARMA PARTNERING

The Nuts & Bolts of Due Diligence in Biopharma Partnering

Learn due diligence best practices from leading global pharmaceutical professionals in this Q&A whitepaper on how to form productive biopharma partnerships.

This whitepaper discusses:

  • What large pharma expects when entering due diligence with a biopharma company

  • The importance of IP due diligence

  • The best ways to present and stage information that is disclosed to a potential partner

  • Common mistakes and how to avoid them

  • How to recognize potential problems and address them early in the process

  • The best practices for the best long-term partnerships

If you are seeking to partner with another biopharmaceutical company, or desire to out- or in-license a drug, you will want to hear these perspectives. Request a copy. 

VIEW THE
WHITEPAPER

WHITEPAPER AUTHOR:

Company team

Linda Pullan, PhD

Pullan Consulting

Linda offers biotech and
pharmaceutical companies consulting
in all aspects of partnering. Linda has
a Ph.D. in Biochemistry, a B.S. in
Chemistry, and more than twenty
years of drug industry
experience. Learn More

Company team

James A. McCarthy, CLP, MBA

Corporate and Business Development, Alliance Management, CorpDev Ventures 

Jim has 30 years of life sciences professional experiences with projects and deals in over 30 countries with over 80 completed agreements across a range of transactions valued in excess of $900 million. His background includes a twenty-five year career with Bristol-Myers Squibb and Eli Lilly & Company and over fifteen years in international corporate business development and licensing roles.

Company team

Natalie Mirutenko, PhD

Transaction and Due Diligence Senior Director for the Center of External Innovation at Takeda

Natalie is an accomplished biopharmaceutical Business Development professional with a strong track record of results oriented achievements in technology, company, and product licensing and acquisition. She has over 35 years of diversified biopharmaceutical experience, with scientific, financial, strategic, and business perspective.

Company team

David L. Snitman, PhD

Partner, DL Snitman Inc and Former COO, Array BioPharma

David is a partner in a biotech business development-consulting agency, DL Snitman Inc. He is a Cofounder of Array BioPharma and lead over a dozen partnering deals, providing more then $600 M in non-dilutive capital. 

Company team

Patrick Gattari, JD

Partner, McDonnell Boehnen Hulbert & Berghoff

Patrick's practice focuses on patent prosecution and technology licensing, with emphasis in biotechnology, pharmaceuticals, diagnostics, and medical devices. His 20-plus years of practice has emphasized patent portfolio management and the licensing, acquisition, and sale of intellectual property. Learn More

Company team

Ann-Marie Costelloe, AFBPS

Psychologist | Executive Consultant, Somerville Partners

With over 20 years of organizational development consulting with organizations, teams and individuals, Ann-Marie directly contributes to financial success by customizing solutions to help leaders increase employee engagement and contributions, align strategy and tactics, and elevate performance across the business. Learn More 

Company team

William Gangi, MS, MBA

Director, Due Diligence Program Manager - Corporate Development, Shire

William currently serves as a Director, Due Diligence Program Manager within the Corporate Development department at Shire. He has 20 years of drug development, commercialization and strategic operations experience within the biopharmaceutical industry.